Tserepro

General characteristics. Structure:

Active agent: 400 mg глицерилфосфорилхолин hydrate (sincaline альфосцерат); excipients: глицерол (glycerin), water cleared. Capsule cover: gelatin medical, глицерол (glycerin), methylparahydroxybenzoate (methylparaben), пропилпарагидроксибензоат (propylparaben), dye ferrous oxide red, titanium dioxide, the water purified sorbitol (sorbite). Capsules are soft gelatinous, oblong shape, from red till brown color. Contents of capsules - the oily, transparent, colourless or slightly painted liquid.

Pharmacological properties:

The central holinostimulyator as a part of which 40,5% of metabolic protected sincaline contain (metabolic protection promotes release of sincaline in a brain). At hit in an organism it is split under the influence of enzymes on sincaline and glycerophosphate: sincaline participates in biosynthesis of acetylcholine — one of the main mediators of nervous excitement; glycerophosphate is a predecessor of phospholipids (phosphatidylsincaline) of a neural membrane. Provides synthesis of acetylcholine and phosphatidylsincaline in neyronalny membranes, improves a blood stream and strengthens metabolic processes in the central nervous system, activates a reticular formation. Increases the linear speed of a blood-groove on the party of traumatic damage of a brain, contributes to normalization of spatio-temporal characteristics of spontaneous bioelectric activity of a brain; exerts positive impact on cognitive and behavioural reactions of patients with vascular diseases of a brain. Improves functions of a brain, influencing pathogenetic factors of an involutional psychoorganic syndrome, changes phospholipidic structure of membranes of neurons and reduces cholinergic activity. Dozozavisimo stimulates allocation of acetylcholine; participating in phosphatidylsincaline synthesis (membrane phospholipid), improves synoptic transfer, plasticity of neyronalny membranes, function of receptors. Does not exert impact on a reproductive cycle and  does not possess teratogenic and mutagen action. The pharmacokinetics Absorption — 88%, easily gets through a blood-brain barrier (at oral administration concentration in a brain — 45% of that in plasma). It is removed preferential easy, in the form of carbon dioxide (85%), and also kidneys and through intestines (15%).

Indications to use:

- The acute and recovery periods of a severe craniocereberal injury and ischemic stroke, the recovery period of a hemorrhagic stroke proceeding with focal polusharny symptomatology or symptoms of defeat of a brainstem;
- a psychoorganic syndrome against the background of degenerative and involutional changes of a brain; chronic insufficiency of cerebral circulation;
- cognitive frustration (disturbances of cogitative function, memory, confusion of consciousness, a disorientation, decrease in motivation, initiative and ability of concentration of attention) including at dementia and encephalopathy;
- senile pseudo-melancholy.

Route of administration and doses:

At acute states: intramusculary or intravenously (slowly) on 1,0 g (1 ampoule) a day for 10–15 days, then pass to reception of capsules inside 0,8 g (2 capsules) in the morning and 0,4 g (1 capsule) in the afternoon within 6 months. At chronicities: inside on 0,4 g (1 capsule) 3 times a day, are preferable to food. Duration of treatment makes 3–6 months.

Features of use:

When developing nausea after administration of drug it is necessary to reduce a dose. Tserepro does not exert impact on speed of psychomotor reactions.

Side effects:

Allergic reactions, nausea (owing to dopaminergic activation).

Interaction with other medicines:

 It is not revealed.

Contraindications:

Hypersensitivity, pregnancy, breastfeeding.

Overdose:

Symptoms: dispeptic frustration. Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

Capsule period of validity — 2 years. Not to use after the term specified on packaging. List B. Capsules: in dry, protected from light and the place, unavailable to children, at a temperature of 25 °C.

Issue conditions:

According to the recipe

Packaging:

Capsules of 400 mg: on 10 or 14 capsules in a blister strip packaging. On 10 or 14 capsules in bank of light-protective glass. Each can or 1 blister strip packaging together with the application instruction in a pack from a cardboard.